Interleukin 6 and Rheumatoid Arthritis

Abstract EN

Interleukin-6 (IL-6) is a representative cytokine featuring pleiotropic activity and redundancy.

A transient synthesis of IL-6 contributes to host defense against infectious agents and tissue injuries by inducing acute phase reactions and immunological and hematopoietic responses.

However, uncontrolled persistent production of IL-6 may lead to the development of several immune-mediated diseases.

Rheumatoid arthritis (RA) is a chronic disease with joint and systemic inflammation resulting from immunological abnormalities and it has been found that IL-6 plays a key role in the development of this disease.

Clinical trials in various parts of the world of tocilizumab, a humanized anti-IL-6 receptor antibody, have proved its efficacy and tolerable safety either as monotherapy or in combination with disease-modifying antirheumatic drugs.

As a result, it is currently used as a first-line biologic for the treatment of moderate-to-severe RA in more than 100 countries.

Clarification of the mechanism(s) through which tocilizumab exerts its effect on RA and of the reason(s) why IL-6 is continuously produced in RA can be expected to lead to the best use of this agent for RA patients and aid in investigations into the pathogenesis of RA.